Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8207465 | PMC |
| http://dx.doi.org/10.1016/j.ekir.2021.04.036 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Transplacental transfer of ravulizumab in a pregnant woman with neuromyelitis optica: a case report.
BMJ Neurol Open
August 2025
Rheumatology, Cleveland Clinic Abu Dhabi, Abu Dhabi, Abu Dhabi, UAE.
Neuromyelitis optica spectrum disorder (NMOSD) is a rare relapsing autoimmune disease of the central nervous system (CNS). Management during pregnancy is challenging due to limited safety data for disease-modifying therapies. We report a case of a 41-year-old woman with aquaporin-4 (AQP4) IgG positive NMOSD who was switched from rituximab to ravulizumab during pregnancy.
View Article and Find Full Text PDF[New treatment strategies for paroxysmal nocturnal hemoglobinuria: drug selection in the era of novel complement inhibitors].
Rinsho Ketsueki
September 2025
Department of Hematology and Oncology, Osaka University Graduate School of Medicine.
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal disorder characterized by complement-mediated hemolysis, thrombosis, and bone marrow failure. Eculizumab (Ecu), a C5 inhibitor, blocks intravascular hemolysis (IVH) and improves prognosis. Ravulizumab and crovalimab have longer half-lives, and reduce treatment burden.
View Article and Find Full Text PDFClinical characteristics and management of paroxysmal nocturnal hemoglobinuria in the Middle East: a narrative review.
Clin Exp Med
August 2025
Hematology Department, Kadhimiya Hematology Center, Baghdad, Iraq.
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematological disorder caused by uncontrolled terminal complement activation of blood cells. It is associated with intravascular hemolysis, thromboembolic events, organ damage, impaired quality of life and premature mortality. As there are no PNH registry data from Middle Eastern countries, little is known about its management in the region.
View Article and Find Full Text PDFSuccessful treatment of severe IVIG-induced immune hemolytic anemia with ravulizumab in a patient with systemic lupus erythematosus: a therapeutic challenge.
Rheumatology (Oxford)
September 2025
Fourth Department of Internal Medicine, School of Medicine, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece.
Effectiveness and Safety of Switching to Ravulizumab From Eculizumab in Kidney Transplant Recipients With Atypical Hemolytic Uremic Syndrome: A Global aHUS Registry Analysis.
Clin Transplant
September 2025
Department of Pediatrics and Medical Genetics, Ghent University Hospital, Ghent, Belgium.
Introduction: Atypical hemolytic uremic syndrome (aHUS) is a disease of complement dysregulation that may lead to kidney failure. Ravulizumab and eculizumab are complement C5 inhibitors approved for the treatment of aHUS. This study assessed the real-world effectiveness and safety of switching to ravulizumab from eculizumab in kidney transplant recipients with aHUS.
View Article and Find Full Text PDF